Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in moderate-severe COVID-19
NCT04357808Phase 2Completed
- Start
- Apr 2020
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sarilumab in coronavirus disease 2019 (COVID-19). Started Apr 2020; status: completed.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04357808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357808.